Treatment considerations in node-positive prostate cancer

Following an initial dose of VIR-5500 of 120 µg/kg or higher, all patients achieved a PSA reduction.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Catch up on all the notable drug and device approvals in urology over the past year.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

The alert was issued to clarify that the devices should not be used for suction and irrigation.

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.